MICA: BRONCH-UK a multicentre and multidisciplinary partnership grant tackling unmet needs in bronchiectasis

Lead Research Organisation: Newcastle University
Department Name: Institute of Cellular Medicine

Abstract

2.1 Unmet Clinical Need

Bronchiectasis (BE) is a progressive respiratory (lung) disease characterised by cough, mucus and severe, recurrent bacterial chest infections with high rates of ill health, time off work and marked reductions in health-related quality-of-life. In almost half of cases, the cause of bronchiectasis is unknown (idiopathic) and treatment in these patients remains "best guess" or symptom driven. Bronchiectasis presents a huge challenge to patients and doctors because no effective treatment is available. Both the world's first national guidelines (authored by coapplicants of this proposal) and Cochrane "best evidence" review of Bronchiectasis confirms this situation, reporting that small single-centre studies with ill-defined patient groups have hampered the few attempts to study clinical interventions /drug trials, rendering them of unproven use.

Previously the MRC sponsored UK trials in Bronchiectasis in the 1950s: Since then major developments have been sorely lacking. This partly reflects a feeling that BE is rare. However recent evidence is against this: In the UK and the US healthcare demands due to BE and mortality rates are increasing with 70,000+ hospital admissions in the UK 2011. Based on projections from US health insurance claims there are 100,000 US patients. We have limited UK data on how common this bronchiectasis is: Experts have however estimated 30-60,000 patients are affected in the UK but recent research suggests over 100,000 are affected.

Whilst the small case series reported so far demonstrate that "unknown cause" (idiopathic) and post-infectious bronchiectasis are the leading causes, bronchiectasis can also complicate common lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) or immune problems e.g. Rheumatoid arthritis. Cystic Fibrosis is an inherited (genetic) form of bronchiectasis which like COPD associated bronchiectasis has different outcomes, microbiology and management needs from Bronchiectasis. Cystic fibrosis is rare (10,000 cases in the UK) yet has made significant gains through multicentre working and coordinating research.

To date no large studies of the genetic causes of idiopathic bronchiectasis have been conducted as this requires large numbers of patients beyond that a single centre can provide. There is currently no registry of well characterised patients with Bronchiectasis anywhere outside the US. The US national registry was commenced recently and has 1200 patients that differ to UK patients. There is an urgent need to build a large cohort of UK patients with Bronchiectasis in which large enough studies can be undertaken; adding in a biobank is a key additional strength.

Brief description of the Cohort and Partnership
The cohort will comprise 3500 symptomatic adult patients with a High Resolution CT scans demonstrating bronchiectasis. Patients will be characterised on the basis of clinical history, clinical examination and detailed investigations that are already part of routine clinical care with yearly reviews. A DNA biobank (from a blood sample) will be collected and will form a world's first in bronchiectasis providing a unique resource allowing future genetic studies to identify underlying genetic causes & new targets for treatment.

The partnership links 9 recruiting centres with established clinics & track records in Bronchiectasis research spread across the UK that have never had funding to work together. Additionally ground-breaking scientific partners with expertise in relevant areas will for the first time allow comprehensive mapping of the knowledge gaps. Future research will be able to use the strength of the assembled cohort; we can deliver a programme of clinical trials that address fundamental issues.

We will therefore tackle three major unmet needs 1) Lack of expertise in the area, 2) Lack of a clinical evidence base 3) Basic science- attracting skilled scientists to work in the area.

Technical Summary

3.1 Technical summary ; Our methodology is to

1) Set up a world leading multi-disciplinary partnership, that addresses translational gaps through collective, but never before, assembled expertise.
2) Develop industry & academia pre-competitive space workshops to define consensus statements, new mechanistic studies/ grants and clinical trials.
3) Biobank DNA & serum from 3500 well characterised databased patients with CT proven BE.
4) Create a large database of well-characterised BE patients to facilitate translational research and clinical trials. Databasing will include multiple fields aligned to national standards of care and additional fields (developed from the US Bronchiectasis database allowing international comparisons). Tagging of records to Office of National Statistics and HES data will allow prognostic indices to be developed.
5) Three Partnership pilot projects will focus on important events that have important mechanistic or pathfinding potential and mandate multicentre & multi-disciplinary approaches:
i) A clinimetrics study of outcome measures in BE Identify and define/ validate clinical outcome measures & biomarkers in an intensive pilot study of 100 patients including lung function (spirometry, lung clearance index), quality of life (QOL-B), culture and quantitative counts with exploratory biomarkers in blood & sputum (as compared to sputum 16SRNA microbiome).
ii) A pilot randomised placebo controlled trial of Pseudomonas aeruginosa bacterial eradication in patients who develop their first infection. This is cross-cutting and studies both patient and bacterial factors involved in P. aeruginosa persistence (16S microbiome analysis & virulence marker expression and human exome sequencing) to help identify vaccine targets.
iii) Identify the prevalence of P. aeruginosa epidemic strains and compare their phenoytpe and genotypes to non-epidemic / BE adapted strains, linking to an international genome project for additional comparative power.

Planned Impact

6.1 The potential for developing new treatments and management strategies using a Bronchiectasis patient cohort was recognised by as a key priority in a roadmap exercise. Assembling this cohort of biobanked patients was chosen as the highest priority for this partnership above all other possible collaborative studies reflecting its pluripotency (see also 4.1, 5.1 & Pathways to Impact file).

The Bronchiectasis Patient Cohort and Biobank will have immediate and long term benefits: It will

i) provide an opportunity for basic science researchers to study a ready assembled well characterised cohort / select particular phenotypes of interest.
ii) identify new targets for drug therapy in the first translational gap through basic science studies.
iii) enable meaningful intervention studies in both the academic and pharmaceutical industry field.
iv) provide information to patients and their families which will help them manage or prevent complications of Bronchiectasis.
v) it will directly shape future patient care through mapping of outcomes and mortality.
vi) inform Department of Health & NHS commissioners of treatment burdens and healthcare use.
vii) allow development of better clinical guidelines for clinicians.

Impact on the first translational gap

Two key drawbacks to tackling "first translational" evidence gaps in bronchiectasis are;
1) The lack of a basic science roadmap of discovery in the field.
2) A lack of a large well characterised cohort that is adequately powered.
These have collectively resulted in understandable barriers to grant awards and successful research in the field. To date, for example, the MRC has funded only 1 study in bronchiectasis in the last 15 years. The impact of the partnership will be to identify such a roadmap across a broad range of scientific disciplines and secondly provide the cohort that is phenotyped/ characterised enough and in sufficient numbers to remove such concerns.

Impact on patient care - development of clinical guidelines.

An accessible, clearly defined patient cohort would fulfil an unmet clinical need to evaluate and optimise current management strategies and provide evidence-based clinical guidelines. It would also be possible to assess disease progression and the impact of physiotherapy on this progression.

Impact on clinical research and trials.

The reasons for variation in progression and the factors that ultimately determine this in bronchiectasis remain unclear. This cohort will be utilised to explore genotype-phenotype correlations in more detail by analysing the physiological, environmental and genetic factors that may be relevant to disease expression. The proposed cohort would also provide sufficient power to assess the efficacy of potential disease-modifying drugs, or novel interventional therapies such as inhaled antibiotic therapy. Proposed joint workshops with academic clinicians, regulatory authorities are expected to improve trials design, feasibility and regulatory approvals. The number and type of studies will be limited by recruitment of the various subgroups of interest e.g. Pseudomonas infected or naïve. Based on projections we would expect to secure funding for and conduct least 3 major interventional studies and 6 observational/proof of principle studies during the 5-year period of funding. Studies are likely to be in the region of 3 months to 3 years duration.

Impact of 'added value'.

This cohort will underpin multiple new studies that would have previously been impossible. This will support the work of multiple scientific beneficiaries across genetics, microbiology, proteomics and immunology.
The recent establishment of a US national database presents a unique opportunity for the field to have truly comparable outcomes. The ability to make a real impact on the lives of patients with this progressive and disabling disease will develop best through a global perspective as afforded by such comparative data.

Publications

10 25 50
 
Description Multi Membership of the British Guidelines group
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
Impact Clear guidance on patient management, risk stratification and service design
 
Description Multi Membership of the European Guidelines group
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
Impact Members of BronchUK contributed to an international guideline on clinical care in bronchiectasis- this will improve clinical care across Europe by standardising aetiological assessment and clarifying best practice
URL http://erj.ersjournals.com/content/50/3/1700629
 
Description Multi Membership of the European Guidelines group; Published International Guidance
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
Impact Clear international guidance on patient management, identification of at risk groups
 
Description Representation on ERS Task Force
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
URL http://taskforces.ersnet.org/item/ers-guidelines-on-the-management-of-adult-non-cystic-fibrosis-bron...
 
Description NIHR HTA Scheme;
Amount £1,500,000 (GBP)
Organisation NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) 
Sector Public
Country United Kingdom
Start 11/2017 
End 06/2020
 
Description US-COPD Foundation
Amount $250,000 (USD)
Organisation COPD Foundation 
Sector Charity/Non Profit
Country United States
Start 07/2016 
End 07/2021
 
Description iABC (inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis) consortium
Amount € 50,000,000 (EUR)
Funding ID 115721 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 08/2015 
End 07/2020
 
Title BronchUK patient registry and database 
Description The database has been developed with the Farr institute and is now containing multicentre data including clinical and therapy information 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? No  
Impact The database now allows us to identify potentially eligible patients for the funded HTA trial and invite them by post- hence this will underpin prognostic research AND clinical intervention studies 
 
Description BronchUK members advise on ORBIT Phase 2 trial 
Organisation Aradigm Corporation
Country United States 
Sector Private 
PI Contribution BronchUK members D Bilton and A De Soyza advised on this pharma funded trial.
Collaborator Contribution Aradigm Corp funded and sponsored this trial.
Impact The findings on this trial were published in Thorax in 2013, doi:10.1136/thoraxjnl-2013-203207.
Start Year 2009
 
Description BronchUK members advised on ORBIT-3 trial 
Organisation Aradigm Corporation
Country United States 
Sector Private 
PI Contribution BronchUK member C Haworth and BronchUK affiliate D Bilton advised on this pharma led study.
Collaborator Contribution Aradigm Corp acted as both sponsor and funder on the trial.
Impact No outputs so far.
Start Year 2014
 
Description BronchUK members as leads on PROMIS trial 
Organisation Profile Pharma Ltd.
Country United Kingdom 
Sector Private 
PI Contribution BronchUK member C Haworth and BronchUK affiliate D Bilton were leads on this pharma sponsored trial.
Collaborator Contribution Profile Pharma Ltd (UK) acted as both funder and sponsor.
Impact Findings from the trial were published in American Journal of Respiratory and Critical Care Medicine in 2014, doi: 10.1164/rccm.201312-2208OC
Start Year 2009
 
Description BronchUK members lead on RESPIRE-1 trial 
Organisation Bayer
Department Bayer HealthCare
Country Germany 
Sector Private 
PI Contribution BronchUK member A De Soyza and BronchUK affiliate R Wilson were key leads on the pharma led RESPIRE-1 trial.
Collaborator Contribution Bayer HealthCare acted as sponsor and funder on this trial.
Impact Presented in Keynote session as oral presentation at ERS meeting 2016. Manuscript in prep.
Start Year 2013
 
Description Industry Partner Funding - Novartis 
Organisation Actavis
Country Ireland 
Sector Private 
PI Contribution BronchUK have used the funding to increase the consortium's impact and influence and to extend the cohort study.
Collaborator Contribution Actavis provided funding to increase the consortium's impact and influence and to extend the cohort study.
Impact No outputs so far.
Start Year 2015
 
Description Industry partner funding - Chiesi 
Organisation Chiesi
Country Italy 
Sector Private 
PI Contribution BronchUK have used this funding to increase the consortium's impact and influence and to extend the cohort study.
Collaborator Contribution Chiesi provided funding to increase the consortium's impact and influence and to extend the cohort study.
Impact No outputs so far.
Start Year 2014
 
Description Industry partner funding - GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution BronchUK have used thisfunding to increase the consortium's impact and influence and to extend the cohort study.
Collaborator Contribution GSK provided funding to increase the consortium's impact and influence and to extend the cohort study.
Impact No outputs so far.
Start Year 2014
 
Description Industry partner funding - Gilead 
Organisation Gilead Sciences, Inc.
Department Gilead
Country United Kingdom 
Sector Private 
PI Contribution BronchUK have used this funding to increase the consortium's impact and influence and to extend the cohort study.
Collaborator Contribution Gilead provided funding to increase the consortium's impact and influence and to extend the cohort study.
Impact No outputs so far.
Start Year 2015
 
Description Members of the Bronch-UK consortium 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation Papworth Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation Queen's University Belfast
Country United Kingdom 
Sector Academic/University 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation Royal Brompton & Harefield NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation University Hospital Llandough
Country United Kingdom 
Sector Hospitals 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation University Hospitals Birmingham NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation University of Dundee
Country United Kingdom 
Sector Academic/University 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation University of Edinburgh
Department Respiratory Medicine Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description Members of the Bronch-UK consortium 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Collaborator Contribution Facilitation of clinical trials and academic research studies in order to improve our understanding of what causes bronchiectasis and to find better, more effective treatment for people with this condition.
Impact Network members have appeared as collaborators or co-applicants on grants and publications. The collaboration is multi-disciplinary including; clinicians with expertise in bronchiectasis, respiratory infection, COPD, physiotherapy and Cystic Fibrosis; basic scientists with interests in bacterial pathogens, genomics, medical statistics and respiratory physiology; a lay member. A £1.8M NIHR HTA grant has been awarded to the Consortium members for the CLEAR trial of mucolytic therapy in bronchiectasis.
Start Year 2014
 
Description British Thoracic Society Meeting Presentation December 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tony De Soyza presented a talk on Bronchiectasis Pipelines and Networks to give the audience an update on developments in
Bronchiectasis and outline pipelines of new studies & therapies in the field.
Year(s) Of Engagement Activity 2014
URL https://www.bronch.ac.uk/Contents/Item/Display/92
 
Description British Thoracic Society Meeting Presentation December 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Two presentations at the British Thoracic Society Meeting December 2015:

Anthony De Soyza - Talk on Sputum Neutrophils but not Interleukin-8 (IL-8) or Interleukin-17 (IL-17) correlate with the Bronchiectasis Severity Index (BSI).
Vidya Navaratnam - Poster on admission trends and outcomes of individuals with bronchiectasis admitted to adult general critical care units in England, Wales and Northern Ireland.
Year(s) Of Engagement Activity 2015
URL https://www.bronch.ac.uk/Contents/Item/Display/111
 
Description BronchUK - Microbiology Meeting, British Library, November 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A number of leading basic scientists and clinical researchers from within and outwith the BronchUK Network attended this meeting with a focus on microbiology in bronchiectasis. The aims of the meeting were to;
• Identify important microbiology research questions for patients with bronchiectasis
• Define feasible cross-disciplinary experimental approaches to answer these questions, and the most effective and up to date methodologies
• Begin to plan applications to obtain funding to actually do the required research
• discuss writing review articles in this field to increase profile

The meeting was a success and has led to collaborations and discussions in how to take the key research areas forward.
Year(s) Of Engagement Activity 2016
 
Description BronchUK Twitter Account 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact A BronchUK twitter account has been created to increase the consortium's visibility among the public and to network with supporters, practitioners in the field, industry and patients.
Year(s) Of Engagement Activity 2015,2016
URL https://twitter.com/Bronch_UK
 
Description European Respiratory Society Meeting Presentations - September 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Bronch-UK researchers were involved in a number of spoken and poster presentations at the ERS meeting in Amsterdam in September 2015.

Talks:

Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC). James Chalmers, Eva Polverino, Anthony De Soyza, Felix Ringshausen, Marlene Murris, Wim Boersma, Antoni Torres, Montserrat Vendrell, J. Stuart Elborn, Francesco Blasi, Stefano Aliberti. On Behalf of the EMBARC Clinical Research Collaboration.

Determinants and assessment of excess cardiovascular risk in bronchiectasis. Aarash Saleh, Bessie Kwok, Jeremy Brown, John Hurst

Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group. Stefano Aliberti, Eva Polverino, Anthony De Soyza, Michael R. Loebinger, Rosario Menendez, Felix C. Ringshausen, Montserrat Vendrell, James D. Chalmers

Posters:

Atorvastatin as an anti-inflammatory in bronchiectasis. Pallavi Bedi, James Chalmers, Adriano Rossi, Adam Hill

Audit investigating self-management of bronchiectasis at University Hospital Llandough, Wales. Sabena Ali, Jamie Duckers, Dawn Lau

The impact of acute air pollution fluctuations on non-cystic fibrosis bronchiectasis pulmonary exacerbations: A case-crossover analysis. Pieter Goeminne, Pallavi Bedi, Michal Kicinski, Lauren Richardson, Kees De Hoogh, Ben Nemery, Tim Nawrot, Michael Loebinger, Adam Hill, Lieven Dupont

Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study. James Chalmers, Melissa McDonnell, Pieter Goeminne, John Davidson, Robert Rutherford, Megan Crichton, Thomas Fardon, Adam Hill, Lieven Dupont, Stefano Aliberti, Anthony De-Soyza

Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB). Anthony De Soyza, Timothy Aksamit, Elisabeth Operschall, Tiemo-Joerg Bandel, Ulrike Krahn, Margarita Criollo, Robert Wilson

Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients. Y.K. Hilliam, A. Perry, A.J. Hall, J. Davison, K.E. Walton, J. Fothergill, A. De Soyza, C. Winstanley
Year(s) Of Engagement Activity 2015
URL https://www.bronch.ac.uk/Contents/Item/Display/110
 
Description International Meeting on Asthma COPD and Concomitant Chronic Diseases Presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tony De Soyza gave a talk at the meeting at the International Meeting on Asthma, COPD and Concomitant Chronic Diseases held in Firenze, Italy 5-7 March 2015.
Year(s) Of Engagement Activity 2014
URL https://www.bronch.ac.uk/Contents/Item/Display/97
 
Description Medicine and me: Living with bronchiectasis (in conjunction with British lung foundation and teh Royal Society for Medicine) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Please see here: https://www.rsm.ac.uk/medandme/bronchiectasis frpm website: he Medicine and Me series of meetings aim to update us all on important medical conditions and gives a direct voice to patients and their carers to share their concerns on the impact of diagnosis, investigation and management.
Physicians, Surgeons and indeed all healthcare professionals continue to learn from and be inspired to greater efforts by our patients to improve care.
The audience at this meeting will comprise of those living with bronchiectasis, their families, carers and advocates, representing about 70% of those present; and clinicians and researchers, representing not more than 30%. Clinicians will include doctors, specialist nurses and others involved in the treatment and care of those who have this condition.
Bronchiectasis patients and carers are invited to this meeting to learn and share experiences in managing this condition. We've consulted an expert and to date there are no studies confirming there is a significant risk of cross-infection between patients with bronchiectasis. We however suggest patients with an active infection or "flare up" do not attend the day. It is highly recommended that you bring a friend or carer if possible.
Year(s) Of Engagement Activity 2017
URL https://www.rsm.ac.uk/medandme/bronchiectasis
 
Description Patient engagement via British Lung Foundation information leaflet; BMA patient information award winner 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact The British Lung foundation identified work done in Newcastle and peer reviewed by BronchUK members. The patient brochure replaces 1 X A4 sheet to a multiple pages patient supported content
Year(s) Of Engagement Activity 2018
URL https://www.blf.org.uk/support-for-you/bronchiectasis
 
Description Talk at British Thoracic Society Meeting, December 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation at the British Thoracic Society Meeting
Year(s) Of Engagement Activity 2016